A388870 Share Price Performance
₩7,100.00
290.00 (4.26%)
Price ₩7,100.00
Share Pricen/a
Pharos iBio Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A388870 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Pharos iBio Co., Ltd. Key Details
About A388870
- Founded
- 2016
- Employees
- n/a
- CEO
- WebsiteView website
Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.
